Survey results showed patients with a history of live biotherapeutic product therapy preferred rectally administered treatment while patients who had not received live biotherapeutic product therapy would be willing to consider it.
Although antibiotics are the standard-of-care treatment for Clostridioides difficile infection, they can cause further microbiota changes that predispose patients to recurrence.
Rebyota is a live biotherapeutic product that is unfamiliar to many pharmacists and other health care providers with different steps in the eventual administration process.